SGLT-2 I after Myocardial Infarction - EMPACT-MI - Dr. Javed Butler (Jackson, MS, USA)

Prof. Dr. Javed Butler presents major results from his EMPACT-MI trial, which – as a phase 3 trial - studied the use of empagliflozin in patients after acute myocardial infarction. Dr. Javed Butler is cardiologist and heart failure expert; he is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi. The interview was recorded on March 21st, 2024. Moderators: Prof. Dr. Marcus Säemann (Vienna, Austria), Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern, Germany) and Prof. Dr. Gunnar Heine (Frankfurt, Germany). Articles discussed: Empagliflozin after Acute Myocardial Infarction. Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF. N Engl J Med 2024 doi: 10.1056/NEJMoa2314051 Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R, Hoole SP, Jones DA, Lee K, Tygesen H, Johansson PA, Langkilde AM, Ridderstråle W, Parvaresh Rizi E, Deanfield J, Oldgren J. NEJM Evid 2024 doi: 10.1056/EVIDoa2300286